知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

34 records (took 0.017 seconds)

    PHARMACEUTICAL COMPOSITION COMPRISING ANTI-TIGIT ANTIBODY AND ANTI-PD-1/ANTI-VEGFA BISPECIFIC ANTIBODY, AND USE THEREOF
    1.
    发明申请
    PHARMACEUTICAL COMPOSITION COMPRISING ANTI-TIGIT ANTIBODY AND ANTI-PD-1/ANTI-VEGFA BISPECIFIC ANTIBODY, AND USE THEREOF 有权

    公开(公告)号：US20250034253A1

    公开(公告)日：2025-01-30

    申请号：US18264138

    申请日：2023-02-14

    Applicant: Akeso Biopharma, Inc.

    Inventor： Yu XIA ,  Zhongmin WANG ,  Baiyong LI

    IPC: C07K16/28 ,  A61K39/00 ,  A61K45/06 ,  A61P35/00 ,  C07K16/22

    Abstract: The present invention relates to the field of pharmaceuticals, particularly to an anti-TIGIT antibody, a pharmaceutical composition, and use thereof, and more particularly to use in combination with an anti-PD-1/anti-VEGFA antibody in preventing or treating a tumor. Specifically, the present invention relates to an anti-TIGIT antibody or an antigen-binding fragment thereof, wherein the antibody comprises a heavy chain variable region comprising HCDR1-HCDR3 having amino acid sequences set forth in SEQ ID NOs: 3-5, respectively; and the antibody comprises a light chain variable region comprising LCDR1-LCDR3 having amino acid sequences set forth in SEQ ID NOs: 8-10, respectively. The antibody of the present invention can effectively bind to TIGIT and has the potential for use in tumor prevention and treatment.

    MONOCLONAL ANTIBODY AGAINST NERVE GROWTH FACTOR, AND ENCODING GENE AND USE THEREOF
    8.
    发明公开
    MONOCLONAL ANTIBODY AGAINST NERVE GROWTH FACTOR, AND ENCODING GENE AND USE THEREOF 审中-公开

    公开(公告)号：US20240025983A1

    公开(公告)日：2024-01-25

    申请号：US18321711

    申请日：2023-05-22

    Applicant: Akeso Biopharma, Inc.

    Inventor： Zhongmin Maxwell WANG ,  Baiyong LI ,  Yu XIA ,  Peng ZHANG

    IPC: C07K16/22 ,  A61P19/02 ,  A61P29/00 ,  C07K16/42

    CPC classification number: C07K16/22 ,  A61P19/02 ,  A61P29/00 ,  C07K16/42 ,  A61K2039/505

    Abstract: The present invention discloses a monoclonal antibody against nerve growth factor, and an encoding gene and use thereof. The monoclonal antibody comprises heavy chains comprising a heavy chain constant region and a heavy chain variable region, and light chains comprising a light chain constant region and a light chain variable region. The heavy chain variable region comprises three complementarity determining regions HCDR1, HCDR2 and HCDR3, and the light chain variable region comprises three complementarity determining regions LCDR1, LCDR2 and LCDR3. The monoclonal antibody can specifically bind to nerve growth factor, and can be used to detect the presence and/or level of nerve growth factor, as well as to prepare a drug for inhibiting the nerve growth factor-dependent proliferation of TF-1 cells, and for treating or preventing at least one of neuropathic pain, chronic pain, and inflammatory pain, thus having good application prospects and marketing value.

    ANTI-IL-1beta ANTIBODY AND PHARMACEUTICAL COMPOSITION THEREOF AND USE OF SAME
    10.
    发明申请
    ANTI-IL-1beta ANTIBODY AND PHARMACEUTICAL COMPOSITION THEREOF AND USE OF SAME 有权

    公开(公告)号：US20210179706A1

    公开(公告)日：2021-06-17

    申请号：US17267115

    申请日：2019-08-13

    Applicant: Akeso Biopharma, Inc.

    Inventor： Baiyong LI ,  Yu XIA ,  Peng ZHANG ,  Zhongmin Maxwell WANG

    IPC: C07K16/24 ,  A61K47/68 ,  A61P19/02 ,  A61P37/06

    Abstract: The present invention belongs to the field of immunology, and relates to an anti-IL-1β antibody and pharmaceutical composition thereof and use of the same. Specifically, the present invention relates to an anti-IL-1β antibody or an antigen-binding fragment thereof, wherein a heavy chain variable region of the antibody comprises HCDR1-HCDR3 with amino acid sequences set forth in SEQ ID NO: 17-SEQ ID NO: 19, respectively; and a light chain variable region of the antibody comprises LCDR1-LCDR3 set forth in SEQ ID NO: 20-SEQ ID NO: 22, respectively. The antibody disclosed herein can effectively bind to human IL-1β, block the binding of IL-1β to a receptor IL-1R1 thereof, and inhibit the activation of downstream signaling pathways of IL-1β; having the potential of being used for preparing a medicament for preventing and treating autoimmune diseases, cryopyrin-associated periodic syndromes in children and adults, systemic juvenile idiopathic arthritis, gouty arthritis, cardiovascular diseases or tumors.

Patent Agency Ranking